Effect of high doses of a sustained-release bovine somatotropin on antibody formation in dairy cows.
Eighty-two lactating Holstein cows received either one, three, or five concurrent, intramuscular injections of a unit dose (.6 g) of zinc methionyl bST (some-tribove) or five doses of the vehicle. Injections were administered at 14-d intervals from 60 d postpartum until the end of lactation or necropsy. Thirty-eight cows continued on the same treatment for a 2nd yr. Blood bST antibodies developed within the first 7 wk of treatment, and the number of cows with anti-bST binding generally declined with time. Thirteen out of 59 cows receiving bST developed binding activity > 25% (positives) during the 1st yr. At the .6-g dose level, no binding was detected after wk 15. Seven of the 13 positive cows were among the group randomly selected to continue on study during yr 2. In the 2nd yr, only 2 out of 24 bST-treated cows were positive. Binding activity was associated with the IgG fraction in serum. Binding capacities of antibodies ranged from .625 to 3.04 mg of bST/L, and affinities ranged from 1.14 x 10(8) to 3.14 x 10(8) L/mol. Cows considered to be clinically positive had performance similar to those of their herdmates having binding < 25%. No evidence of a pathologic effect of antibodies existed in treated cows, their calves, or fetuses. The presence of anti-bST antibodies did not affect milk production of the cow or growth of the calves conceived during bST treatment.
Eppard
P J
PJ
Monsanto Company, Animal Sciences Division, St. Louis 63198.
Rogan
G J
GJ
Boysen
B G
BG
Miller
M A
MA
Hintz
R L
RL
Hammond
B G
BG
Torkelson
A R
AR
Collier
R J
RJ
Lanza
G M
GM
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D002417:Cattle / Q000276:immunology*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology*; D007273:Injections, Intramuscular / Q000662:veterinary
D003692:Delayed-Action Preparations; D013006:Growth Hormone